Product Name:4-(5,6,7,8-Tetrahydro-1,8-naphthyridin-2-yl)butanoic acid hydrochloride

IUPAC Name:4-(5,6,7,8-tetrahydro-1,8-naphthyridin-2-yl)butanoic acid hydrochloride

CAS:193818-31-4
Molecular Formula:C12H17ClN2O2
Purity:95%
Catalog Number:CM258502
Molecular Weight:256.73

Packing Unit Available Stock Price($) Quantity
CM258502-1g 1-2 Weeks ſȌǕ

For R&D use only.

Inquiry Form

   refresh    

Product Details

CAS NO:193818-31-4
Molecular Formula:C12H17ClN2O2
Melting Point:-
Smiles Code:O=C(O)CCCC1=NC2=C(CCCN2)C=C1.[H]Cl
Density:
Catalog Number:CM258502
Molecular Weight:256.73
Boiling Point:
MDL No:MFCD22690488
Storage:

Category Infos

Pyridines
Pyridine is a six-membered heterocyclic compound containing one nitrogen heteroatom. Pyridine and piperidine are the most frequently occurring heterocyclic building blocks in drug molecules. According to incomplete statistics, there are currently more than 180 drugs containing pyridine or piperidine structure that have been marketed, nearly 1/5 of the drugs approved for marketing in recent years contain these two structures.
Pyridine | C5H5N | Pyridine Supplier/Distributor/Manufacturer - Chemenu
Pyridine,Pyridine Wholesale,Pyridine for Sale,Pyridine Supplier,Pyridine Distributor,Pyridine Manufacturer
Pyridine is a basic heterocyclic organic compound with the chemical formula C5H5N. It is structurally related to benzene, with one methine group (=CH−) replaced by a nitrogen atom. It is a highly flammable, weakly alkaline, water-miscible liquid with a distinctive, unpleasant fish-like smell.
Naphthyridines
Naphthyridine is a class of aromatic heterocyclic compounds whose chemical formula is C8H6N2. They consist of naphthalene bicyclic rings in which two carbon atoms are replaced by nitrogen atoms. There are ten isomers of naphthyridine, because naphthyridine has two benzene rings, has strong π-π conjugation, and has better luminescence properties. Common naphthyridines are 1,8-naphthyridines. There are many kinds of 1,8-naphthyridine derivatives, and they are widely used.

Column Infos

Bexotegrast
Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.

Related Products